Valuation : Ligand Pharmaceuticals Incorporated

Market Cap 5.78B 4.97B 4.66B 4.27B 7.96B 546B 8.03B 55.17B 21.49B 279B 21.69B 21.22B 899B P/E 2026 *
55.3x
P/E 2027 * 33.9x
Enterprise Value 5.78B 4.97B 4.66B 4.27B 7.96B 546B 8.03B 55.17B 21.49B 279B 21.69B 21.22B 899B EV / Sales 2026 *
19.9x
EV / Sales 2027 * 15.2x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+3.39%
Current month+2.08%
1 month-3.59%
3 months+22.93%
6 months+38.79%
Current year+53.38%
1 week 275.6
Extreme 275.6
290.41
1 month 275.6
Extreme 275.6
317.49
Current year 175.89
Extreme 175.89
326.63
1 year 161.82
Extreme 161.82
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap. Importance
12/8/26 Exercice

Chief Financial Officer

94,923 0.4736%
12/8/26 Exercice

Director

19,414 0.0969%
3/8/26 Exercice

General Counsel

15,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+3.39%+72.89%+356.48% 5.78B
-1.05%-2.17%+54.68%+105.87% 1,034B
-0.77%+3.48%+55.17%+72.63% 671B
-1.15%+1.34%+21.55%+77.21% 460B
-0.18%-0.86%+28.98%+38.02% 353B
-1.10%+5.11%+25.15%+46.09% 309B
-0.82%+0.74%-1.07%+12.80% 255B
-1.29%+1.97%+57.42%+73.58% 240B
-1.17%+0.85%-17.34%-54.53% 207B
-0.25%+3.47%+33.67%+100.55% 188B
Average -0.75%+1.33%+33.11%+82.87% 372.25B
Weighted average by Cap. -0.90%+1.05%+37.10%+67.66%

Financials

2026 *2027 *
Net sales 290M 249M 234M 214M 400M 27.4B 403M 2.77B 1.08B 14B 1.09B 1.06B 45.09B 381M 327M 307M 281M 525M 35.97B 529M 3.63B 1.42B 18.38B 1.43B 1.4B 59.2B
Net income 112M 96.23M 90.31M 82.62M 154M 10.57B 155M 1.07B 416M 5.4B 420M 411M 17.4B 187M 161M 151M 138M 258M 17.67B 260M 1.79B 695M 9.03B 702M 687M 29.08B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
04/09/26 US$290.00 +0.09% 8,138
03/09/26 US$289.74 +0.98% 190,728
02/09/26 US$286.92 +0.93% 189,615
01/09/26 US$284.27 +0.06% 185,017
31/08/26 US$284.10 +1.29% 203,701
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
289.74USD
Average target price
342.82USD
Spread / Average Target
+18.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock